Alnylam Pharmaceuticals (ALNY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 09-2025 | 06-2025 | 03-2025 | 12-2024 | |
| Sales | 1,097,033 | 1,249,026 | 773,689 | 594,189 | 593,166 |
| Cost of Goods | 267,723 | 200,154 | 142,953 | 71,041 | 102,817 |
| Gross Profit | 829,310 | 1,048,872 | 630,736 | 523,148 | 490,349 |
| Operating Expenses | 698,315 | 681,044 | 647,888 | 505,112 | 596,325 |
| Operating Income | 131,718 | 367,982 | -16,199 | 18,077 | -105,159 |
| Interest Expense | 129,337 | 44,398 | 40,246 | 38,646 | 38,971 |
| Other Income | 158,756 | -84,615 | 21,087 | -21,027 | -49,828 |
| Pre-tax Income | 161,137 | 238,969 | -35,358 | -41,596 | -193,958 |
| Income Tax | -25,282 | -12,115 | 30,919 | 15,883 | -110,195 |
| Net Income Continuous | 186,419 | 251,084 | -66,277 | -57,479 | -83,763 |
| Net Income | $186,419 | $251,084 | $-66,277 | $-57,479 | $-83,763 |
| EPS Basic Total Ops | 1.43 | 1.91 | -0.51 | -0.44 | -0.66 |
| EPS Basic Continuous Ops | 1.44 | 1.91 | -0.51 | -0.44 | -0.66 |
| EPS Diluted Total Ops | 1.44 | 1.84 | -0.51 | -0.44 | -0.66 |
| EPS Diluted Continuous Ops | 1.45 | 1.83 | -0.51 | -0.44 | -0.66 |
| EPS Diluted Before Non-Recurring Items | N/A | 1.84 | -0.52 | -0.44 | -0.65 |
| EBITDA(a) | $145,224 | $381,785 | $-2,255 | $32,482 | $-90,991 |